Home / Market News / $EXEL

$EXEL news and market catalysts

The 15 most recent market catalysts affecting $EXEL, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

15 catalysts 4 high impact 6 bullish 5 bearish Biotechnology
Nov 2, 2026 Corporate Catalyst Bullish Impact 55
HC Wainwright & Co. Maintains Buy Rating and Raises Price Target for Exelixis
HC Wainwright & Co. maintained its 'Buy' rating for Exelixis and raised its price target from $56 to $78, representing a 39.3% increase. This new target implies a 12.4% upside from…
Oct 30, 2026 Corporate Catalyst Neutral Impact 55
Analyst Rating and Price Target Updates for Exelixis, Inc.
On October 30, 2026, TD Cowen, Barclays, and Truist Securities all raised their price targets for Exelixis, Inc., with TD Cowen maintaining a 'Buy' rating, Barclays an 'Equal-Weigh…
Oct 30, 2026 Corporate Catalyst Bullish Impact 55
Barclays Raises Price Target for Exelixis, Inc.
Barclays has raised its price target for Exelixis, Inc. to $54 from $49, reflecting an updated valuation based on the company's latest quarterly financial results and operational d…
Oct 29, 2026 Corporate Catalyst Neutral Impact 65
Exelixis Announces Third Quarter 2026 Financial Results and Provides Corporate Update
Exelixis released its Q3 2026 financial results, a standard quarterly event for publicly traded companies. The filing also included updates on its key drug, cabozantinib, and the p…
Oct 29, 2026 Corporate Catalyst Bearish Impact 92
EXEL Industries Reports Annual Revenue Decline for 2025–2026
EXEL Industries experienced a substantial 13.0% annual revenue decline for the 2025–2026 fiscal year, with a 4.7% drop in Q4. This significant underperformance is attributed to a d…
Oct 19, 2026 Corporate Catalyst Bullish Impact 60
Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65
Citizens analyst Silvan Turkcan has maintained a 'Market Outperform' rating on Exelixis and raised the price target from $55 to $65. This action signals a strong belief in the comp…
Oct 9, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51
RBC Capital's decision to maintain a 'Sector Perform' rating while raising the price target for Exelixis from $45 to $51 suggests a nuanced view. The increased price target indicat…
Sep 11, 2026 Corporate Catalyst Bearish Impact 65
Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In
The FDA extended the review period for Exelixis's zanzalintinib NDA by three months, pushing the action date to March 3, 2027. This delay, triggered by updated safety and efficacy …
Sep 11, 2026 Corporate Catalyst Neutral Impact 75
Exelixis Announces Three-Month FDA Review Period Extension For Its Zanzalintinib New Drug Application In Combination With Atezolizumab For The Treatment Of Metastatic Colorectal Cancer
Exelixis submitted updated safety and efficacy data for its Zanzalintinib New Drug Application in response to an FDA information request. The FDA deemed this a 'major amendment,' w…
Aug 19, 2026 Corporate Catalyst Neutral Impact 55
BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54
BMO Capital analyst David Lebowitz has initiated coverage on Exelixis (EXEL) with a 'Market Perform' rating and a $54 price target. This event introduces a new institutional perspe…
Aug 6, 2026 Corporate Catalyst Bullish Impact 55
Stifel Maintains Hold on Exelixis, Raises Price Target to $51
Stifel analyst Stephen Willey maintained a 'Hold' rating on Exelixis but raised the price target from $47 to $51. This indicates that while the analyst sees some increased value in…
Aug 6, 2026 Corporate Catalyst Bearish Impact 85
Exelixis shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.
The headline indicates a direct negative impact on Exelixis (EXEL) due to company-specific news. Mixed Q2 results, while not entirely negative, combined with a cut in future sales …
Aug 5, 2026 Corporate Catalyst Bearish Impact 85
Exelixis shares are trading lower after the company reported mixed Q2 financial results and cut its FY26 sales guidance below estimates.
This headline represents a significant corporate catalyst for Exelixis. The combination of 'mixed' Q2 results, implying some disappointment in recent performance, and a 'cut' to th…
Aug 5, 2026 Corporate Catalyst Bearish Impact 75
Exelixis Lowers FY2026 Sales Guidance from $2.525B-$2.625B to $2.500B-$2.550B vs $2.595B Est
Exelixis has lowered its FY2026 sales outlook from a range of $2.525 billion-$2.625 billion to $2.500 billion-$2.550 billion. This new guidance is also below the analyst consensus …
Aug 5, 2026 Corporate Catalyst Bullish Impact 85
Exelixis Q2 Adj. EPS $0.91 Beats $0.79 Estimate, Sales $628.700M Miss $635.951M Estimate
Exelixis announced its Q2 earnings, revealing a substantial beat on adjusted EPS ($0.91 vs. $0.79 estimate), representing a 21.33% increase year-over-year. However, the company's s…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.